Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective
Abnormal accumulation of Tau protein is closely associated with neurodegeneration and cognitive impairment and it is a biomarker of neurodegeneration in the dementia field, especially in Alzheimer’s disease (AD); therefore, it is crucial to be able to assess the Tau deposits in vivo. Beyond the flui...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/23/13002 |
| _version_ | 1797507738488537088 |
|---|---|
| author | Maria Ricci Andrea Cimini Riccardo Camedda Agostino Chiaravalloti Orazio Schillaci |
| author_facet | Maria Ricci Andrea Cimini Riccardo Camedda Agostino Chiaravalloti Orazio Schillaci |
| author_sort | Maria Ricci |
| collection | DOAJ |
| description | Abnormal accumulation of Tau protein is closely associated with neurodegeneration and cognitive impairment and it is a biomarker of neurodegeneration in the dementia field, especially in Alzheimer’s disease (AD); therefore, it is crucial to be able to assess the Tau deposits in vivo. Beyond the fluid biomarkers of tauopathy described in this review in relationship with the brain glucose metabolic patterns, this review aims to focus on tauopathy assessment by using Tau PET imaging. In recent years, several first-generation Tau PET tracers have been developed and applied in the dementia field. Common limitations of first-generation tracers include off-target binding and subcortical white-matter uptake; therefore, several institutions are working on developing second-generation Tau tracers. The increasing knowledge about the distribution of first- and second-generation Tau PET tracers in the brain may support physicians with Tau PET data interpretation, both in the research and in the clinical field, but an updated description of differences in distribution patterns among different Tau tracers, and in different clinical conditions, has not been reported yet. We provide an overview of first- and second-generation tracers used in ongoing clinical trials, also describing the differences and the properties of novel tracers, with a special focus on the distribution patterns of different Tau tracers. We also describe the distribution patterns of Tau tracers in AD, in atypical AD, and further neurodegenerative diseases in the dementia field. |
| first_indexed | 2024-03-10T04:52:44Z |
| format | Article |
| id | doaj.art-d1c26e0538b6491c811a99dede8e7001 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T04:52:44Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-d1c26e0538b6491c811a99dede8e70012023-11-23T02:31:33ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-11-0122231300210.3390/ijms222313002Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future PerspectiveMaria Ricci0Andrea Cimini1Riccardo Camedda2Agostino Chiaravalloti3Orazio Schillaci4Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, ItalyDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, ItalyDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, ItalyDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, ItalyDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, ItalyAbnormal accumulation of Tau protein is closely associated with neurodegeneration and cognitive impairment and it is a biomarker of neurodegeneration in the dementia field, especially in Alzheimer’s disease (AD); therefore, it is crucial to be able to assess the Tau deposits in vivo. Beyond the fluid biomarkers of tauopathy described in this review in relationship with the brain glucose metabolic patterns, this review aims to focus on tauopathy assessment by using Tau PET imaging. In recent years, several first-generation Tau PET tracers have been developed and applied in the dementia field. Common limitations of first-generation tracers include off-target binding and subcortical white-matter uptake; therefore, several institutions are working on developing second-generation Tau tracers. The increasing knowledge about the distribution of first- and second-generation Tau PET tracers in the brain may support physicians with Tau PET data interpretation, both in the research and in the clinical field, but an updated description of differences in distribution patterns among different Tau tracers, and in different clinical conditions, has not been reported yet. We provide an overview of first- and second-generation tracers used in ongoing clinical trials, also describing the differences and the properties of novel tracers, with a special focus on the distribution patterns of different Tau tracers. We also describe the distribution patterns of Tau tracers in AD, in atypical AD, and further neurodegenerative diseases in the dementia field.https://www.mdpi.com/1422-0067/22/23/13002Tau tracersfirst-generation Tau tracerssecond-generation Tau tracerstauopathyTau biomarkersPET |
| spellingShingle | Maria Ricci Andrea Cimini Riccardo Camedda Agostino Chiaravalloti Orazio Schillaci Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective International Journal of Molecular Sciences Tau tracers first-generation Tau tracers second-generation Tau tracers tauopathy Tau biomarkers PET |
| title | Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective |
| title_full | Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective |
| title_fullStr | Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective |
| title_full_unstemmed | Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective |
| title_short | Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective |
| title_sort | tau biomarkers in dementia positron emission tomography radiopharmaceuticals in tauopathy assessment and future perspective |
| topic | Tau tracers first-generation Tau tracers second-generation Tau tracers tauopathy Tau biomarkers PET |
| url | https://www.mdpi.com/1422-0067/22/23/13002 |
| work_keys_str_mv | AT mariaricci taubiomarkersindementiapositronemissiontomographyradiopharmaceuticalsintauopathyassessmentandfutureperspective AT andreacimini taubiomarkersindementiapositronemissiontomographyradiopharmaceuticalsintauopathyassessmentandfutureperspective AT riccardocamedda taubiomarkersindementiapositronemissiontomographyradiopharmaceuticalsintauopathyassessmentandfutureperspective AT agostinochiaravalloti taubiomarkersindementiapositronemissiontomographyradiopharmaceuticalsintauopathyassessmentandfutureperspective AT orazioschillaci taubiomarkersindementiapositronemissiontomographyradiopharmaceuticalsintauopathyassessmentandfutureperspective |